



## Emerald Health Therapeutics Announces Private Placement

**VICTORIA, BC, October 4, 2016** – Emerald Health Therapeutics Inc. (TSXV: EMH) ("Therapeutics") is pleased to announce a proposed private placement (the "Offering") of up to 4,411,764 units (a "Unit") of the Company with Emerald Health Sciences Inc. ("Sciences"), a creditor and major shareholder of Therapeutics at a price of \$0.68 per Unit. Each Unit will consist of one common share and one common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder thereof to acquire an additional common share at a price of \$0.85 per common share for a period of five years from the closing date. Closing of the Offering is conditional upon, among other things, approval of the TSX Venture Exchange.

The proceeds of the Offering will be used for general working capital purposes and all securities issued pursuant to the Offering will be subject to a hold period expiring four months and a day following the date of issue.

Sciences currently holds approximately 39,030,937 of the issued and outstanding shares of Therapeutics and upon issuance of the common shares under the Offering, will hold approximately 64.6% on an undiluted basis.

As Sciences is an insider of the Company, the participation in the Offering is considered to be a "related party transaction", as defined under Multilateral Instrument 61-101 ("MI 61-101"). The Company intends to rely on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(b) and 5.7(a).

### **Emerald Health Therapeutics Inc.**

Emerald Health Therapeutics wholly owns Emerald Health Botanicals. Emerald Health Botanicals holds a License under the Marihuana for Medical Purposes Regulations (Canada) to cultivate and sell medical cannabis out of its facility located in Victoria, British Columbia. It also holds a Supplemental License to produce and sell medical cannabis oils and capsules.

ON BEHALF OF THE BOARD

"Avtar Dhillon"  
Executive Chairman

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

#### Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future plans, programs, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to the private placement offering and the number of and price of shares to be issued and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, failure to obtain approval of the TSX Venture Exchange, failure to negotiate final transaction documents, failure to meet conditions precedent to closing of the private placement offering. Actual results may differ materially from those expressed or implied by such forward-looking statements.

For further information: Please contact Sandy Pratt at 250-818-9838 or [ir@emerald.care](mailto:ir@emerald.care).